EyePoint Pharmaceuticals, Inc. (FRA:PV3B)
Germany
· Delayed Price · Currency is EUR 12.10
+0.61 (5.31%)
At close: Dec 4, 2025
EyePoint Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 74.58 | 99.7 | 281.26 | 95.63 | 178.59 | 44.91 | Upgrade
|
| Short-Term Investments | 129.45 | 271.21 | 49.79 | 48.93 | 32.97 | - | Upgrade
|
| Cash & Short-Term Investments | 204.02 | 370.91 | 331.05 | 144.56 | 211.56 | 44.91 | Upgrade
|
| Cash Growth | -19.61% | 12.04% | 129.00% | -31.67% | 371.08% | 102.16% | Upgrade
|
| Receivables | 1.05 | 0.61 | 0.81 | 15.5 | 18.35 | 9.45 | Upgrade
|
| Inventory | 2.11 | 2.31 | 3.91 | 2.89 | 3.62 | 5.34 | Upgrade
|
| Prepaid Expenses | 8.03 | 8.08 | 8.03 | 9.08 | 4.22 | 3.42 | Upgrade
|
| Other Current Assets | 0.9 | 1.41 | 1.01 | 0.78 | - | - | Upgrade
|
| Total Current Assets | 216.11 | 383.31 | 344.8 | 172.81 | 237.75 | 63.12 | Upgrade
|
| Property, Plant & Equipment | 29.52 | 29.18 | 10.23 | 7.4 | 2.73 | 3.24 | Upgrade
|
| Other Intangible Assets | - | - | - | - | 22.75 | 25.21 | Upgrade
|
| Other Long-Term Assets | 6.07 | 5.98 | 0.15 | 0.15 | 0.15 | 0.15 | Upgrade
|
| Total Assets | 251.7 | 418.47 | 355.18 | 180.36 | 263.37 | 91.72 | Upgrade
|
| Accounts Payable | 10.08 | 11.72 | 6.5 | 5.92 | 7.39 | 4.81 | Upgrade
|
| Accrued Expenses | 17.88 | 17.96 | 16.76 | 15.34 | 11.45 | 7.34 | Upgrade
|
| Short-Term Debt | - | - | - | 10.48 | - | - | Upgrade
|
| Current Portion of Leases | 1.96 | 1.25 | 0.56 | 0.54 | 0.78 | 0.69 | Upgrade
|
| Current Unearned Revenue | - | 17.78 | 38.59 | 1.21 | 1.07 | 0.95 | Upgrade
|
| Other Current Liabilities | 0.18 | 0.34 | 0.84 | 1.05 | 2.97 | 1.11 | Upgrade
|
| Total Current Liabilities | 30.09 | 49.05 | 63.26 | 34.54 | 23.66 | 14.89 | Upgrade
|
| Long-Term Debt | - | - | - | 29.31 | 36.56 | 37.98 | Upgrade
|
| Long-Term Leases | 21.3 | 21.86 | 4.91 | 5.98 | 1.9 | 2.4 | Upgrade
|
| Long-Term Unearned Revenue | - | 10.85 | 20.69 | 13.56 | 14.56 | 15.62 | Upgrade
|
| Other Long-Term Liabilities | 0.12 | 0.21 | - | 0.6 | 2.32 | 2.29 | Upgrade
|
| Total Liabilities | 51.51 | 81.96 | 88.86 | 83.99 | 78.99 | 73.18 | Upgrade
|
| Common Stock | 0.07 | 0.07 | 0.05 | 0.03 | 0.03 | 0.02 | Upgrade
|
| Additional Paid-In Capital | 1,237 | 1,208 | 1,008 | 766.9 | 752.6 | 528.36 | Upgrade
|
| Retained Earnings | -1,037 | -873.02 | -742.15 | -671.35 | -569.1 | -510.68 | Upgrade
|
| Comprehensive Income & Other | 0.92 | 1.03 | 0.86 | 0.79 | 0.84 | 0.84 | Upgrade
|
| Shareholders' Equity | 200.18 | 336.5 | 266.32 | 96.37 | 184.38 | 18.54 | Upgrade
|
| Total Liabilities & Equity | 251.7 | 418.47 | 355.18 | 180.36 | 263.37 | 91.72 | Upgrade
|
| Total Debt | 23.26 | 23.11 | 5.47 | 46.31 | 39.24 | 41.07 | Upgrade
|
| Net Cash (Debt) | 180.76 | 347.81 | 325.58 | 98.25 | 172.32 | 3.84 | Upgrade
|
| Net Cash Growth | -21.64% | 6.83% | 231.38% | -42.98% | 4382.78% | - | Upgrade
|
| Net Cash Per Share | 2.63 | 6.18 | 8.37 | 2.63 | 5.99 | 0.30 | Upgrade
|
| Filing Date Shares Outstanding | 82.79 | 68.73 | 49.83 | 34.3 | 34.04 | 28.74 | Upgrade
|
| Total Common Shares Outstanding | 69.57 | 68.27 | 49.04 | 34.08 | 33.91 | 18.14 | Upgrade
|
| Working Capital | 186.01 | 334.26 | 281.54 | 138.27 | 214.09 | 48.23 | Upgrade
|
| Book Value Per Share | 2.88 | 4.93 | 5.43 | 2.83 | 5.44 | 1.02 | Upgrade
|
| Tangible Book Value | 200.18 | 336.5 | 266.32 | 96.37 | 161.63 | -6.67 | Upgrade
|
| Tangible Book Value Per Share | 2.88 | 4.93 | 5.43 | 2.83 | 4.77 | -0.37 | Upgrade
|
| Construction In Progress | - | 1.51 | 3.73 | - | - | - | Upgrade
|
| Leasehold Improvements | - | 4.13 | 1.01 | 1.01 | 0.26 | 0.26 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.